Frequent expression of PD-L1 on circulating breast cancer cells.
about
Stem-like features of cancer cells on their way to metastasisCheckpoint Inhibitors and Their Application in Breast CancerCirculating tumor cells in breast cancerCirculating and disseminated tumor cells: diagnostic tools and therapeutic targets in motionClinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?Short term ex-vivo expansion of circulating head and neck tumour cells.PD-L1 expressing circulating tumour cells in head and neck cancers.Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients.The potential for liquid biopsies in the precision medical treatment of breast cancer.The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.Enrichment of circulating head and neck tumour cells using spiral microfluidic technology.Mechanism of immune evasion in breast cancer.Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.Phenotype of circulating tumor cell: face-off between epithelial and mesenchymal masks.Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsiesFunctional studies on circulating and disseminated tumor cells in carcinoma patientsSubtype-specific prognostic impact of different immune signatures in node-negative breast cancer.Clinical and biological significance of circulating tumor cells in cancer.Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancerEpithelial-mesenchymal plasticity and circulating tumor cells: Travel companions to metastases.Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.The promise of circulating tumor cells for precision cancer therapy.Epithelial-mesenchymal plasticity in circulating tumor cells.Circulating tumor cells: clinical validity and utility.Integrating liquid biopsies into the management of cancer.Characterization of single circulating tumor cells.Circulating Tumor Cells as Cancer Biomarkers in the Clinic.Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor NivolumabCirculating Tumor Cells: Moving Biological Insights into Detection.Biology and clinical significance of circulating tumor cell subpopulations in lung cancerLiquid biopsy: Potential and challenges.Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.Quantifying HER-2 expression on circulating tumor cells by ACCEPT.A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry.Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer.Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology.A Collective Route to Head and Neck Cancer Metastasis.Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
P2860
Q26741641-6CD4F18D-0E85-4A84-813B-19C71162A354Q26745442-3CB1AB06-B5B0-463E-A6B2-F73B4DF59DBDQ26774808-71161AC0-4B7D-4487-AC59-00FD8358B529Q28066285-8AAADEE8-0D47-49F7-8B21-EAEBFF948651Q28084351-1E504239-6BB9-4678-8311-3B146733D8B1Q30361741-4152BE09-4289-4B0F-871D-2755ECBCA144Q33697273-C6B1F2B1-48C0-4DD8-B290-81CF88597344Q33825515-D3EE6D99-AB84-40C0-B542-A507285598CDQ36849660-49728549-285F-43C9-82C1-4AD59C5E8F1EQ37046786-E8E3BB8A-B17E-49A0-AB91-E4132A15B88DQ37642572-11A1E41B-EF13-4BFB-B07F-475FBC635D48Q37712385-0FE34F61-3F55-469C-89EE-44E311C48A01Q38629357-8CE814D1-BDAD-430E-BB63-6149861F10B9Q38693785-05ABA45F-C323-41F0-AF45-B5776C0F502DQ38700222-6DB0FD5F-5257-4298-8960-0057E1D64685Q38723767-196470D0-7EF9-4EEB-9EF6-0B2D9EA7CFE6Q38741582-7FC43FE6-EC81-405F-8CA0-3BE4C81F1EF7Q38743200-2CE5809D-0DE0-4EA5-B169-6AE8FB798857Q38773250-B2118E6F-7455-4CDC-A080-BCC8014B23D8Q38838108-A0F9434A-AF83-48DA-AB76-A493226D9008Q38958563-EAE53565-12FD-4253-A1D0-2A3077757DB1Q39031157-C0935BDA-5295-4C99-AE83-16881F340363Q39053335-DA33B68D-8EF4-4C56-910D-5D4EA0F6F129Q39151285-83855312-73B9-4DDE-A0D7-70DF33A5BFF7Q39157824-30187DDC-0E8C-4B5E-B115-E23DD7B1AD25Q39275082-7B579B45-3038-4B4B-87F2-FD89D4EF9558Q39339875-7B87A29C-7265-40E7-A040-EB5670861856Q39641921-3311A3E0-1C0F-4813-853F-51C0952FED42Q41333886-1463774B-CDE3-471A-8954-0158139E0BAAQ41430303-FE6DBE3B-331A-4AFD-8A14-3D2E78E01C3EQ41605032-F265B88C-31DD-4BE2-BA27-1E4528E92BC4Q42337624-7A5CD41F-88CE-4123-B91B-48B03E387DEEQ42506382-2776F29B-379A-40E2-8013-98F1F33F682BQ42700740-F4FD5340-A9A0-4D2D-A34B-FCF70B1A4D58Q47103859-DF354A46-39F2-4850-B735-619730564153Q47104764-53AA18DC-F349-4B97-B44D-BEAE408F3289Q47110464-FD757376-58A4-4CFB-8123-C765BDC2B586Q47153925-CADEBA2A-E010-4036-AD2E-BBFF8B7F3FF8Q48240241-815F2767-A427-4B07-964C-0CFD2DCD2D0EQ48353102-F8E7249D-BEF2-453B-964E-14C8609F58FC
P2860
Frequent expression of PD-L1 on circulating breast cancer cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Frequent expression of PD-L1 on circulating breast cancer cells.
@en
type
label
Frequent expression of PD-L1 on circulating breast cancer cells.
@en
prefLabel
Frequent expression of PD-L1 on circulating breast cancer cells.
@en
P2093
P2860
P50
P1433
P1476
Frequent expression of PD-L1 on circulating breast cancer cells.
@en
P2093
Delphine Topart
Kai Bartkowiak
Klaus Pantel
Laure Cayrefourcq
Martine Mazel
Thierry Maudelonde
William Jacot
P2860
P304
P356
10.1016/J.MOLONC.2015.05.009
P577
2015-06-09T00:00:00Z